About the Company

AB Science is a biotechnology company developing masitinib for the treatment of inflammatory diseases, central nervous system diseases, and oncology. Masitinib is an oral tyrosine kinase inhibitor that specifically targets mast cells, an important contributor to many disease states. The Company employs a comprehensive clinical development approach and is currently conducting 13 Phase III clinical trials with masitinib. Several futility and interim analyses are expected in the next 12-24 months and final data from a study in systemic mastocytosis are expected in mid-2015.

Source: LifeSci Capital, LLC research report

Research analyst certification and important disclosures can be found in the full research report. To access the full research report, please click on the link below.

Recent Research